8-K: Iovance Biotherapeutics' AMTAGVI Receives FDA Accelerated Approval for Advanced Melanoma, Marking First Solid Tumor T-Cell Therapy

Iovance Biotherapeutics' AMTAGVI (lifileucel) has received accelerated FDA approval as the first T-cell therapy for a solid tumor, specifically for advanced melanoma after prior treatments.

Summary

• Iovance Biotherapeutics has announced that AMTAGVI (lifileucel) received accelerated approval from the U.S. FDA for treating advanced melanoma.
• AMTAGVI is the first FDA-approved T-cell therapy for a solid tumor and is intended for patients who have previously been treated with a PD-1 blocking antibody and, if applicable, a BRAF inhibitor.
• The approval is based on the C-144-01 clinical trial, which showed a 31.5% objective response rate in a pivotal cohort of 73 patients, with a median duration of response not reached at 18.6 months follow-up.
• A supporting pooled efficacy set of 153 patients showed a 31.4% objective response rate with a median duration of response not reached at 21.5 months follow-up.
• Iovance has approximately $346.3 million in cash, cash equivalents, investments, and restricted cash as of December 31, 2023.
• AMTAGVI is manufactured using a proprietary process to collect and expand a patient's unique T-cells from their tumor.
• The company is also conducting a Phase 3 trial, TILVANCE-301, to confirm clinical benefit.
• Iovance's manufacturing facility in Philadelphia, the iCTC, has the capacity to produce AMTAGVI for several thousand patients annually, with expansion plans underway.

Sentiment

Score: 9

Explanation: The document is highly positive due to the FDA approval of AMTAGVI, strong clinical trial results, and the company's solid financial position. The company is also expanding its manufacturing capacity and has a clear path forward for further development and commercialization.

Positives

• AMTAGVI provides a new treatment option for advanced melanoma patients who have limited options after failing initial therapies.
• The therapy has demonstrated deep and durable responses in clinical trials.
• Iovance has a dedicated manufacturing facility with significant capacity and expansion plans.
• The company has a comprehensive support program, IovanceCares, for patients and treatment centers.
• The company has a strong cash position of approximately $346.3 million as of December 31, 2023.
• The company is actively expanding the use of TIL therapy into other solid tumor types.

Negatives

• AMTAGVI has a boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment.
• The treatment requires lymphodepletion and a short course of high-dose PROLEUKIN (aldesleukin), which can have side effects.
• The manufacturing process for AMTAGVI takes approximately 34 days from tumor tissue receipt to product availability.
• The accelerated approval requires a confirmatory Phase 3 trial to maintain approval.

Risks

• The commercial success of AMTAGVI depends on market acceptance, pricing, and reimbursement.
• Manufacturing challenges could impact the commercial launch.
• Clinical trial results from collaborators may not be reflected in Iovance's sponsored trials.
• The company may not become profitable in the near term.
• Future competitive or market factors may adversely affect the commercial potential of AMTAGVI.
• The company is subject to risks related to regulatory approvals and clinical trial outcomes.
• Unanticipated expenses may decrease cash balances and increase capital requirements.

Future Outlook

Iovance plans to expand the use of AMTAGVI into other solid tumor types, pursue full approval for AMTAGVI in post-anti-PD-1 melanoma, and continue to develop its TIL therapy platform. They also plan to submit a marketing authorization application to the EMA in the first half of 2024 and additional ex-US submissions in the second half of 2024.

Management Comments

• Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President of Iovance, stated that the approval of AMTAGVI is the first step in realizing Iovance's ambition to usher in the next generation of cell therapy.
• Samantha R. Guild, J.D., President, AIM at Melanoma Foundation, expressed that AMTAGVI offers hope to those with advanced melanoma.
• Steven Rosenberg, M.D., Ph.D., Chief, Surgery Branch, National Cancer Institute, noted that the approval reflects significant advancements in TIL cell therapy.
• Dr. Alexander N. Shoushtari, Melanoma Oncologist & Cellular Therapist at Memorial Sloan Kettering Cancer Center, is excited by the potential of AMTAGVI as a new treatment option.
• Dr. Jae Park, Chief of Cellular Therapy Service at Memorial Sloan Kettering Cancer Center, added that this is an important step forward in harnessing cell therapy to treat solid tumors.

Industry Context

This announcement is significant as it marks the first FDA approval of a T-cell therapy for a solid tumor, which has been a major challenge in the field of oncology. It positions Iovance as a leader in the development of TIL therapies and could potentially transform the treatment landscape for advanced melanoma and other solid tumors. The approval also highlights the growing importance of personalized medicine and cell-based therapies in cancer treatment.

Comparison to Industry Standards

• The 31.5% objective response rate in the pivotal cohort of the C-144-01 trial is competitive with other advanced melanoma treatments, particularly in the post-anti-PD-1 setting where response rates are typically lower.
• The median duration of response not reached at 18.6 months follow-up is also promising, suggesting a durable benefit for patients.
• Compared to CAR T-cell therapies, which have shown success in hematological malignancies, AMTAGVI represents a significant advancement in solid tumor treatment.
• Companies like Kite Pharma and Novartis have pioneered CAR T-cell therapies, but these have not been as effective in solid tumors, making Iovance's achievement a notable breakthrough.
• The development of a scalable manufacturing process at the iCTC is also a key differentiator for Iovance, as manufacturing has been a bottleneck for many cell therapy companies.

Stakeholder Impact

• Shareholders will likely see a positive impact due to the FDA approval and potential for revenue generation.
• Patients with advanced melanoma will have a new treatment option.
• Employees will be involved in the commercial launch and expansion of the company.
• Healthcare providers will have a new tool to treat advanced melanoma.
• Suppliers and contract manufacturers will benefit from increased demand for TIL therapy.

Next Steps

• Iovance will execute the commercial launch of AMTAGVI in the first quarter of 2024.
• The company will onboard 50 Authorized Treatment Centers (ATCs) within 90 days of the PDUFA date.
• Iovance will submit a marketing authorization application to the EMA in the first half of 2024.
• The company will submit additional ex-US regulatory dossiers in the second half of 2024.
• Iovance will meet with the FDA to discuss the NSCLC registrational path and frontline study.
• The company will continue to enroll patients in clinical trials for advanced melanoma, NSCLC, and gynecological cancers.
• Iovance will advance new products toward the clinic, including additional genetically-modified TIL therapies.

Key Dates

Keywords

AMTAGVI, lifileucel, melanoma, T-cell therapy, TIL therapy, immunotherapy, FDA approval, solid tumor, cell therapy, Iovance Biotherapeutics